KN026
Drug timelines are a Plus or Pro feature.
10 regulatory and trial events tracked for KN026, covering 2022-06-22 to 2026-04-08. Get the full timeline:
Most recent: Clinical Trial Update: A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer [Phase 3]